Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CD38 | P28907 | 2/20 | 0.43 |
| ▸ | TOP1 | P11387 | 2/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841333 | 0.82 | ABL1 (0.44) | ABL1SMN1; SMN2TP53MAPTTHRB | |
| SCHEMBL6844575 | 0.81 | CYP11B1 (0.47) | ABL1CD38DDR1GRM4TEK | |
| SCHEMBL6846615 | 0.77 | MAPT (0.40) | ABL1SMN1; SMN2TP53MAPTTHRB | |
| SCHEMBL7500274 | 0.76 | BRAF (0.49) | ABL1SMN1; SMN2MAPTTOP1GRM4 | |
| SCHEMBL6841384 | 0.75 | ABL1 (0.41) | ABL1SMN1; SMN2TP53MAPTTHRB | |
| SCHEMBL3974651 | 0.73 | ALDH1A1 (0.44) | ABL1MAPTCD38DDR1GRM4 | |
| Hydrochloric Acid SCHEMBL3971651 | 0.73 | ALDH1A1 (0.43) | ABL1MAPTCD38DDR1GRM4 | |
| SCHEMBL3972148 | 0.71 | CYP1A2 (0.49) | ABL1MAPTCD38ALDH1A1LMNA | |
| SCHEMBL3974655 | 0.71 | SLC9A1 (0.44) | ABL1MAPTCD38GRM4TEK | |
| Hydrochloric Acid SCHEMBL6837522 | 0.70 | SLC9A1 (0.44) | ABL1MAPTCD38GRM4TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | ABL1 555/4885SMN1; SMN2 4682/4885TP53 397/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | ABL1 555/4885SMN1; SMN2 4682/4885TP53 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.